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ABSTRAK
Pengurus Besar Perkumpulan Gastroenterologi Indonesia (PB PGI) menyusun suatu konsensus nasional 
mengenai tatalaksana perdarahan saluran cerna bagian atas non-variseal (Non-variceal upper gastrointestinal 
bleeding/NVUGIB). Hal ini merupakan upaya untuk meningkatkan kualitas pelayanan pasien NVUGIB terkait 
ulkus peptikum. Adapun penyusunan konsensus ini merujuk pada tiga konsensus terbaru dalam tatalaksana 
NVUGIB dengan melakukan modifikasi dari proses Delphi untuk menyusun panduan klinis. Ketiga konsensus 
yang menjadi rujukan tersebut, antara lain: The International Consensus Recommendations on the Management 
of Patients with Non-variceal Upper Gastrointestinal Bleeding (ICON-UGIB), 2010; Asia-Pacific Working 
Group consensus on non-variceal upper gastrointestinal bleeding, 2011; dan Management of Patients With 
Ulcer Bleeding, ACG guidelines,2012.
Konsensus ini disusun agar menjadi rujukan bagi para praktisi medis di seluruh Indonesia dalam 
penatalaksanaan pasien dengan perdarahan saluran cerna bagian atas non-variseal terkait ulkus peptikum. 
Namun, teknik pelaksanaanya sangat tergantung dengan fasilitas diagnostik dan terapeutik yang ada pada 
masing-masing pusat pelayanan kesehatan.
Kata kunci: endoskopi, perdarahan, perdarahan saluran cerna bagian atas non-variseal/NVUGIB, ulkus 
peptikum.
ABSTRACT
The Indonesian Society of Gastroenterology has compiled a national consensus guideline for the management 
of non-variceal upper gastrointestinal bleeding (NVUGIB). It is an endeavor to raise the quality of service 
for NVUGIB patients associated with peptic ulcer. The references for developing this consensus include three 
recent consensus guidelilnes on the management of NVUGIB and a modification of Delphi process was done 
to develop clinical guidelines. The three references are: The International Consensus Recommendations on the 
Management of Patients with Non-variceal Upper Gastrointestinal Bleeding (ICON-UGIB), 2010; Asia-Pacific 
Working Group consensus on non-variceal upper gastrointestinal bleeding, 2011; and Management of Patients 
with Ulcer Bleeding, ACG guidelines, 2012. 
The consensus is compiled as a reference for Indonesian medical practitioners all across the country on 
the management of patients with non-variceal upper gastrointestinal bleeding associated with peptic ulcer. 
However, the technical implementation extremely depends on diagnostic and therapeutical facilities available 
in each health care center.
Key words: endoscopy, bleeding, non-variceal upper gastrointestinal bleeding/NVUGIB, peptic ulcer.
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INTRODUCTION 
Non-variceal upper gastrointestinal bleeding 
Perdarahan saluran cerna bagian atas non-
variseal is a quite common clinical condition; 
however in general, the incidence tends to 
decline in peptic ulcer disease.
There are 3 recent consensus guidelines on 
this topic, which are: The International Consensus 
Recommendations on the Management of 
Patients with Non-variceal UpperGastrointestinal 
Bleeding (ICON-UGIB), 20101; Asia-Pacific 
Working Group consensus on non-variceal 
upper gastrointestinal bleeding, 20112; and 
Management of Patients With Ulcer Bleeding, 
ACG guidelines, 2012.3 Those consensus 
guidelines have used the most recent data about 
the management of NVUGIB by modifying the 
Delphi process in order to compile a clinical 
guideline. Although the guidelines do provide 
a comprehensive recommendation and utilize 
the most recent data from literatures, The 
International Consensus Recommendations of 
2010 and the ACG guidelines 2012, but there is 
no room for specific needs of limited-resources 
countries and ethnic differences.
As an example, the use of proton pump 
inhibitors to reduce the degree of endoscopic 
lesion and the needs of interventional endoscopy 
are recommended by the ICON-UGIB. This gives 
a great financial burden to Asia Pacific countries, 
which have limited resources. Moreover, there is 
no well-defined recommendation about the route 
of administration for PPI, either by intravenous 
or oral route. Furthermore, it is realized that 
there are great differences on the degree of 
Helicobacter pylori infection,1 drug metabolism 
and the use of anti-thrombotic drugs, which may 
affect the management of NVUGIB.1,2 Most of 
the abovementioned issues have been addressed 
attemptively when compiling the Asia Pacific 
guideline and Indonesia has also participated 
during the development of the guideline. 
However, it is also realized that Indonesia has 
great differences from other countries regarding 
the limited availability of medical facilities and 
infrastructures for NVUGIB management.
The major limation is the availability of 
endoscopy, which is the back bone issue in 
NVUGIB management. Therefore, the task force 
in the Organizing Committee of Indonesian 
Society of Gastroenterology has attempted to 
develop a national consensus on the management 
of UGIB associated with peptic ulcer. It is 
an endeavor to bridge the varied availability 
of medical facilities and infrastructure in 
Indonesia in order to raise the quality of service 
for patients who have UGIB associated with 
peptic ulcer. Moreover, the consensus may also 
serve as a professional recommendation for all 
medical practitioners in Indonesia regarding 
the management of patients with non-variceal 
upper gastrointestinal bleeding that associated 
with peptic ulcer. However, the technical 
implementation extremely depends on diagnostic 
and therapeutical facilities available in each 
health care center.
EPIDEMIOLOGY
An endoscopic study in patients with 
dyspepsia symptoms that has been conducted in 
several big cities in Indonesia demonstrates that 
peptic ulcer, i.e. gastric and duodenal ulcers, is 
listed in he top five causes of dyspepsia.4
The incidence of UGIB indicates that there 
are great geographical variations, starting from 
48 to 160 cases per 100,000 populations with a 
higher incidence in male and elderly patients. It 
can be explained due to various causes including 
the different definition of UGIB, population 
characteristics, different prevalence of drug-
induced ulcer and Helicobacter pylori.5,6 Despite 
the optimal management using therapeutical 
endocopy and treatment using gastric acid 
suppressants, the overall mortality of UGIB 
remains stable in recent decades, which ranges 
between 6-14%. Nevertheless, most deaths are 
not caused directly by massive blood loss, but 
much more by intolerance to blood loss, shock, 
aspiration and therapeutical procedures.
The mortality due to UGIB is associated 
with elderly age and severe comorbidity. The 
risk of mortality is also increased by recurrent 
bleeding, which is a major outcome parameter.5,7 
There is a wide range of recurrent bleeding 
in patients with UGIB from 5% to more than 
20%, which depends on several factors, i.e.: 1) 
The etiology of bleeding – it is more common 
due to variceal bleeding and rarely due to small 
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mucosal lesion such as Mallory-Weiss tear.8 2) 
Timing and adequate treatment of endocscopy 
– recurrent most likely occurs in early period of 
treatment and 24 hours are considered to be the 
most optimal time for endoscopic treatment.7,9
Peptic ulcer bleeding (PUB) is the most 
common cause of UGIB. The incidence ranges 
between 31% and 67% of all cases, which is 
followed by erosive gastritis, variceal bleeding, 
esophagitis, malignancy and Mallory-Weiss tear. 
In a subgroup of patients with PUB, the 
incidence of bleeding due to duodenal ulcer is 
slightly higher than that caused by gastric ulcer.5,9 
In Indonesia, there is a different distribution, 
the old data revealed that approximately 70% 
UGIB is caused by ruptured esophageal varices. 
Nevertheless, since there are increased care on 
chronic liver disease and raising population of 
elderly patients, it is estimated that the proportion 
of bleeding caused by peptic ulcer will also 
increase.8,10,11
Data from one of hospitals in Indonesia 
(Sanglah Hospital, Bali) reveal that the most 
common cause of gastrointestinal bleeding 
is peptic ulcer, which is followed by erosive 
gastritis.12 Based on a retrospective study, which 
was performed in 4,154 patients who underwent 
endoscopy in 2001-2005 at the Endoscopic 
Center of Cipto Mangunkusumo Hospital, 
Jakarta, there are about 807 (20.15%) patients 
who have experienced UGIB. The study also 
demonstrates that the most common cause of 
UGIB is ruptured esophageal varices (280 cases; 
33.4%) followed by peptic ulcer bleeding (225 
cases; 26,9%), and erosive gastritis (219 cases; 
26.2%) (Table 1).13
RISK FACTORS FOR PEPTIC ULCER
As seen in Figure 1, H. pylori infection is a 
major factor in the development of ulcers, both 
duodenal and gastric ulcers. The data were taken 
from studies on western countries populations. 
Although they may have a list with similar order, 
it is estimated that in developing countries, 
H.pylori plays a more significant role.14
The evaluation of clinical staging is an 
important early management step. Elderly 
age, multiple comorbidity and hemodynamic 
instability call for aggressive treatment. 
Regardless of the general clinical guideline, a 
systematical staging has been developed.
Table 1. The most common causes of UGIB in patients 
who underwent endocopy at the Endoscopic Center of 
Cipto Mangunkusumo Hospital in 2001-2005
Causes Cases Percentage (%)
Ruptured esophageal varices 280 33.4
Peptic ulcer bleeding 225 26.9
Erosive gastritis 219 26.2
Not found 38 4.5
Others 45 9.0
Total 807 100
unknown
ZES, others
NSAID
H.pylori
infection
DUODENAL ULCER GASTRIC ULCER
unknown
ZES, others
NSAID
H.pylori
infection
Figure 1. Proportion of risk factors for peptic ulcer.14
RISK STRATIFICATION FOR RECURRENT 
BLEEDING AND MORTALITY
Rockall Scoring System is the most utilized 
scoring system, which provides an estimation 
risk for bleeding and mortality. The scoring 
system is developed based on three clinical 
factors and two endoscopic factors. These factors 
are presented in Table 2.
Rockall scoring system may range between 
0-11; while the score of 0-2 is associated with 
good prognosis. Another scoring system, which 
is the Blatchfor scoring system only utilizes 
laboratory and clinical factors and therefore, 
it is recommended for Asian patients in the 
recent Asia-Pasific consensus guideline.2 Unlike 
Rockall Scoring System, the major outcomes 
of this scoring system may predict the needs of 
clinical intervention such as endoscopy, surgery 
or blood transfusion. Blatchford Scoring System 
(Table 3) ranges between 0-23; which the 
scores of 6 or higher are considered to require 
intervention.
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Some risk factors are also associated with 
bad prognosis after the bleeding incident 
associated with peptic ulcer (Table 4). If this 
occurs, clinicians must be more aggressive in 
determining the management that will be carried 
out.
DIAGNOSIS
History Taking 
The most common signs and symptoms 
of upper gastrointestinal tract bleeding are 
hematemesis (vomiting of blood), coffee ground 
emesis and melena (black tarry stool). About 
30% of patients with ulcer bleeding present 
with hematemesis, 20% with melena and 50% 
with both. Hematochezia (fresh blood in stool) 
usually indicates that the source of bleeding is 
in the lower gastrointestinal tract as the upper 
gastrointestinal bleeding will turn into black 
and tarry color during their passage through the 
GI tract resulting in melena. However, 5% of 
patients who experienced ulcer bleeding may 
present with hematochezia, which characterizes 
severe bleeding that usually is more than 1,000 
mL. Patients who present with hematochezia 
and other hemodynamic instability signs such as 
syncope, postural hypotension, tachycardia and 
shock must be considered as patients with upper 
gastrointestinal tract bleeding.
Table 2. Rockall scoring system1
Variables Score 0 Score 1 Score 2 Score 3
Age (year) <60 60-79 >80 -
Shock None Pulse Rate >100x/
minute, BP normal
Pulse Rate >100x/minute, 
Systolic BP <100 mmHg -
Comorbidity None
-
Ischemic heart disease, 
congestive heart failure, and 
any major comorbidity
Renal failure, hepatic 
failure, metastasis
Endoscopy 
diagnosis
Mallory-Weiss Tear, 
no lesion observed, 
no stigmata of recent 
hemorrhage
Peptic ulcer, 
esophagitis, or 
erosive disease
Malignancy of upper GI tract  
-
Stigmata  of 
endoscopic or 
recent hemorrhage 
Clean ulcer base, flat 
pigmented spot -
Blood in upper GI tract,  active 
bleeding, visile vessel without 
bleeding or adherent clot 
-
Table 3. The Blatchford scoring system to determine the 
needs of intervention5
Variables Points Variables Points
Systeolic blood pressure 
(mmHg)
Hemoglobin  
(male; g/dL)
 - 100-109 1  - 12.0-12.9 1
 - 90-99 2  - 10.0-11.9 3
 - <90 3  - <10.0 6
Ureum (mg/dL) Hemoglobin (female; g/dL)
 - 36.5-44.5 2  - 10.0-11.9 1
 - 44.6-55.5 3  - <10.0 2
 - 55.6-139.9 4
 - >140 6
Other variables
 - Pulse rate >100 1
 - Presentation with 
melena 
1
 - Hepatic disease 2
 - Heart failure 2
Total
Table 4. Risk factors that characterize bad prognosis in 
patients with peptic ulcer bleeding14
Age >60 years
Bleeding onset at the hospital
Comorbid medical
Shock or orthostatic hypotension
Fresh blood in nasogastric tube
Coagulopathy
Requirement of repeated transfusion
Ulcer at the upper part of lesser curvature (near the left 
gastric artery)
Ulcer at the posterior duodenal bulb (near the 
gastroduodenal artery)
Endoscopic findings of arterial bleeding or visible blood 
vessel
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Non-specific signs and symptoms including 
nausea, vomiting, epigastric pain, vasovagal 
phenomenon and syncope as well as the most 
common comorbidities (such as diabetes 
mellitus, coronary heart disease, stroke, chronic 
kidney disease and arthritis) and the history of 
medication must also be identified.5,8,14
Physical Examination 
Evaluation on hemodynamic status (pulse 
rate and blood pressure), respiratory rate, level of 
consciousness, pale conjunctiva, slow capillary 
refill time and no stigmata of chronic liver 
cirrhosis, which are the early symptoms, must 
be identified immediately.
Tachycardia on rest and orthostatic 
hypotension indicate a considerably large 
amount of blood loss. Low urine output, dry lips 
and collapse of jugular veins are relatively useful 
signs. It should be noted that tachycardia may not 
appear if the patient is on medication with beta 
blocker drugs, which are commonly used for 
patients with heart failure and liver cirrhosis.5,8,14
Further Assessment 
Although it is not a routine procedure for 
peptic ulcer bleeding, inserting nasogastric tube 
(NGT) and evaluating the aspirate are usually 
useful for early clinical assessment. If bright 
red blood is detected, then the patient needs 
immediate endoscopic evaluation and should 
be managed at the intensive care unit. Reduced 
hemoglobin level of 1g/dL is associated with 
250 mL blood loss. If there is any coffee ground 
emesis, then the patient needs hospitalization 
and endoscopic evaluation within 24 hours. 
However, normal aspirate does not exclude 
gastrointestinal tract bleeding. About 15% of 
patients with normal aspirate remain to have 
active gastrointestinal tract bleeding or high risk 
for recurrent bleeding.5,8,14 Endoscopy detects 
not only peptic ulcer, but also can be utilized to 
evaluate stigmata associated with increased risk 
of recurrent bleeding (Figure 2).
Forrest Classification is used to categorize 
findings during endoscopic evaluation with 
following description: Ulcer with active spurting 
(Forrest IA); Ulcer with oozing bleeding (Forrest 
IB); Ulcer with non-bleeding visible vessel 
(Forrest IIA); Ulcer with adherent clot (Forrest 
IIB); Ulcer with flat pigmented spot (Forrest 
IIC); and Clean-based ulcers (Forrest III).
Patients at high risk of rebleeding without 
treatment are those with active arterial bleeding 
(90%), the occurrence of a non-bleeding visible 
vessel (50%)  an adherent clot (33%).5,8,14
COMPLICATION
Complication that may occur due to peptic 
ulcer bleeding is hypovolemic shock, which may 
be followed with acute renal failure, multi organ 
failures and death.
TREATMENT
Early Management
An appropriate early evaluation and 
resuscitation are important measures that should 
be carried out for patients with UGIB, especially 
for those who present with hematemesis, 
massive hematochezia, melena or progressive 
anemia. We suggest early management with 
multidisciplinary approach involving an internist/
gastroenterologist, an interventional radiologist 
and a surgeon/digestive surgeon.9,14,15
Stratification of the patient into low or high 
risk category for recurrent bleeding and mortality 
may be carried out using Blatchford and Rockall 
Scoring System (in keeping with the availability 
of endocopy facility). Patients with high risk 
for recurrent bleeding and mortality should be 
hospitalized in Intensive Care Unit.5,14
Nasogastric tube (NGT) is inserted for the 
assumed ongoing bleeding, which is accompanied 
A B C
D E F
Figure 2. Endoscopic stigmata of recent hemorrhage of 
a peptic culter. A. active bleeding with spurting; B.Oozing 
bleeding; C. Visible vessel with an adjacent clot; D. Adherent 
clot. E. Based pigmented spot; F. a clean-based ulcer.
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with hemodynamic instability. The purpose of 
NGT insertion is to prevent aspiration, provide 
gastric decompression and evaluate bleeding; 
therefore, it is not necessarily performed in all 
patients with bleeding.3 Nasogastric or orogastric 
lavage can be performed in patients with 
upper gastrointestinal tract bleeding in certain 
circumstances. Ice water is not recommended 
for gastric lavage.3
Resuscitation measures include administration 
of intravenous fluid, oxygen supplementation, 
correction of severe coagulopathy and blood 
transfusion as needed.
The threshold for blood transfusion depends 
on general medical condition and vital signs of 
the patients, but it is usually set at a hemoglobin 
level of ≤7.0 g/dL unless if there is ongoing or 
massive bleeding and there is comorbidity of 
coronary heart disease, hemodynamic instability 
(hypotension and tachycardia) and elderly age.9
The minimal hemoglobin level required 
for endoscopy is 8 mg/dL and if a therapeutical 
endoscopy will be provided, the minimal 
hemoglobin level is 10 mg/dL and the patient 
should have a stable hemodynamic status. Pre-
endoscopic PPI therapy can be recommended 
(1B recommendation) for patients with PUB. 
The acidic environment may cause inhibition 
of platelet aggregation and plasma coagulation, 
which may also result in lysis of the already 
formed clots. Administration of PPI therapy 
can rapidly neutralize intraluminal gastric acid, 
which results in stabilization of blood clot. In 
long term, antisecretory therapy also promotes 
mucosal healing. A recent study shows that pre-
endoscopic PPI therapy has significantly reduced 
high-risk stigmata at early endoscopy (37% vs. 
46%, OR 0.67; 95% CI 0.54-0.84). However, it 
shows no effect on recurrent bleeding, mortality 
and surgery.16
When endoscopy will be delayed and can 
not be performed, an intravenous PPI therapy is 
recommended to reduce further bleeding.3
Timing of Endoscopy 
Endoscopy has become a major tool 
of diagnosis and treatment of UGIB. This 
procedure allows identification of the bleeding 
source and provides treatment in the same 
session. Emergency endoscopy allows for early 
hemostatis, but it can potentially lead to blood 
aspiration and oxygen desaturation in unstable 
patients. In addition, excessive amounts of 
blood and clots may disturb targeted therapy for 
bleeding focus, which may cause the necessary 
repeated endoscopic procedures.3,9,14
The international consensus and Asia Pacific 
guidelines recommend early endoscopy within 
24 hours after the patients have been hospitalized, 
as this treatment significantly reduces the length 
of hostpital stay and improve clinical outcome. 
The very early endoscopy (<12 hours) so 
far has not been shown to give additional 
advantages in terms of reduced risk for recurrent 
bleeding, surgery and mortality. However, 
emergency endoscopy should be considered in 
patients with severe bleeding. In patients with 
clinical manifestation of greater risks (such as 
tachycardia, hypotension, hematemesis or bright 
red blood in NGT), an endoscopy within 12 hours 
may increase clinical outcome.1-3
In patients with stable hemodynamic status 
and without any serious comorbidity, endoscopy 
should be performed first before discharging the 
patient from hospital.3
Endoscopic Therapy for PUB
The aim of therapeutic endocopy is to stop 
active bleeding and prevent recurrent bleeding. 
Several techniques, including injection, ablative 
and mechanical treatment have been developed 
over recent decades. The selection of treatment 
can be adjusted according to the appearance of 
bleeding focus and related risk for persistent 
and recurrent bleeding (Figure 3). In PUB, 
patients with active bleeding or non-bleeding 
visible vessel in ulcer beds are at the highest 
risk for recurrent bleeding; therefore, they need 
immediate endoscopic hemostatic therapy. 
Patients with low-risk stigmata (a clean-based 
ulcer or a pigmented spot in ulcer beds) do not 
need endoscopic therapy.3,7
Patients with clean-based ulcers may have 
a soft diet and be discharged after endoscopy 
assuming they have a stable hemodynamic status, 
adequate hemoglobin level and they have no 
other medical problems.3 Patients with active 
ulcer bleeding, hemostasis therapy shuld be 
given in combination (epinephrine in addition 
to other modalities such as hemoclip placement, 
Vol 46 • Number 2 • April 2014                               National consensus on management of NVUGIB in Indonesia
169
thermocoagulation and electrocoagulation). 
Epinephrine injection is not recommended as 
single therapy. Injection with clip placement is 
recommended as it may reduce the incidence of 
recurrent bleeding.3,14
Patients who endoscopically have high-
risk stigmata (active bleeding, visible vesells, 
clots (according to the Forrest Clasification)) 
are generally hospitalized for 3 days if there is 
no recurrent bleeding and no other indication 
for hospitalization. The patients can have clear 
liquid diet soon after the endoscopy and the 
diet should be customized gradually.3 Patients 
with recurrent bleeding can usually be managed 
with endoscopic therapy. However, emergency 
surgery or angiographic embolization may 
be needed under certain circumstances, such 
as: spurting bleeding that can not be stopped 
by endoscopy, non-visible bleeding spot due 
to massive active bleeding, and recurrent 
bleeding that occurs after the second therapeutic 
endoscopy.
POST-ENDOSCOPIC MANAGEMENT
Antisecretory Therapy
Pharmacotherapy plays a second major 
role in the treatment of UGIB due to peptic 
ulcer. PPI therapy is more superior compared 
to the histamine-2 receptor antagonist. PPI 
can be administered orally or intravenously 
depending on the bleeding stigmata (Forrest 
Classification). Available data have recommended 
the administration of high-dose continuous 
intravenous PPI therapy for PUB patients with 
high-stigmata risks.
Patients with PUB should also be discharged 
with a prescription for a single-daily-dose oral 
PPI to reduce the risk of recurrent bleeding. The 
duration and dose of PPI depend on the etiology 
and any other medication use. In patients with 
idiopathic (non-H.pylori, non-NSAID) ulcers 
can be recommended to have long-term antiulcer 
therapy (such as daily PPI). In patients with 
low-dose aspirin-associated bleeding ulcers, the 
urgent need for aspirin should be re-assessed.1,2,14
H. pylori Eradication Therapy
H. pylori test is recommended in all patients 
with PUB. The test is subsequently followed with 
eradication therapy for all patients who have 
positive results, continuous monitoring to assess 
the results of this therapy and renewed treatment 
for those with failed eradication.
The triple therapy eradication has a successful 
rate of 80% or even 90% in peptic-ulcer patients 
without any significant side effects and has 
a minimal effect on antibiotic resistance. 
Furthermore, regarding the evaluation of 
ulcer healing by endocopy, it is found that the 
success rate of one-week PPI therapy reaches 
80—85%. After eradication of H. pylori has 
been confirmed, no maintance therapy of PPI is 
necessary unless in patients who are NSAIDs or 
antithrombotic users.
Diagnostic test for H. pylori has a low 
negative predictive value in acute UGIB. It 
may be due to technical difficulties to perform 
a representative biopsy or inaccuracy of the 
test in an alkaline environment caused by the 
blood. Negative results of biopsy obtained in the 
acute setting must be carefully interpreted and 
when necessary, repetition of the test should be 
performed during the follow up.1-3,9,17
Active bleeding
or non-bleeding
visible vessel
Adheren clot
Flat pigmented
spot or clean
base
Endoscopic
therapy
Can be considered
as endoscopic
therapy*
without
endoscopic
therapy
Intravenous
PPI therapy
bolus + Drip
Intravenous
PPI therapy
bolus + Drip
Oral PPI
therapy
Figure 3. The management options including endoscopic 
and intravenous PPI treatment for patients with UGIB 
associated with peptic ulcer. PPI = proton pump inhibitor. *If 
the endoscopic therapy facility is optimal.
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Non-variceal Upper Gastrointestinal Bleeding
Resuscitation
(Oxygen, fluid and blood supplementation*)
Pre-endoscopic PPI therapy
Endoscopy within 24 hours (in keeping with
the available facilities)
No lesion
detected
Interventional
radiology/surgery
Lesion
detected
High-risk lesion Adheren clot** Flat spot, clean base
Endoscopy
Therapy
Is the patient stable?
 Hospitalization for
>24-hour monitoring
Continue with
administration of PPI
 Hospitalization in
the ward
 PPI
Reassessment
Recurrent bleeding
 Repeat
endoscopy***
 Consider surgery
or interventional
radiology
 Discharge with a
prescription of PPI
treatment, if possible
 Schedule the follow-up
 Consider test for H. pylori
and treatment
Test result for
H. pylori (+)
Test result for
H. pylori (-)
Eradication
with three
drugs / triple
therapy
Repeat the
test when
necessary
Successful eradication
1 month
yes No
No
yes
Note:
*Hb <7 g/dL, massive,
continuous bleeding, CHD,
hemodynamic instability,
elderly age
** If the facility of endoscopic
therapy is optimal
*** Repeat first-look
endoscopy, if there is
recurrent bleeding : repeat
endoscopy. Second - look
endoscopy, if there is still
bleeding, consider surgery or
interventional radiology.
Initial Assessment
(exclude the possibility of varices, cirrhosis)
Stop PPI therapy (unless for
patients who are NSAIDs or
antithrombotic users).
Figure 4.
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